Welcome to our dedicated page for Interpace Biosciences news (Ticker: IDXG), a resource for investors and traders seeking the latest updates and insights on Interpace Biosciences stock.
Interpace Biosciences, Inc. reports news centered on molecular diagnostic testing through Interpace Diagnostics, with a current focus on thyroid cancer risk assessment. The company’s commercial thyroid offering pairs ThyGeNEXT, a next-generation sequencing assay for thyroid nodules, with ThyraMIRv2, a proprietary microRNA expression profiler and algorithmic classifier.
Recurring updates cover thyroid test volume, revenue, cash collections, reimbursement developments, scientific presentations and business results. Company news also includes capital-structure actions such as repayment of outstanding debt, conversion of preferred stock into common stock, and the completed discontinuation of PancraGEN as Interpace shifted to a thyroid-focused diagnostics model.
Interpace Biosciences (OTCQX: IDXG) reported Q1 2026 revenue of $9.0 million, income from continuing operations of $0.8 million, and Adjusted EBITDA of $1.6 million (17% margin). Thyroid revenue grew 12% year-over-year on 10% higher volume, with gross margin rising to 65% from 59% Pro Forma. Management reaffirmed 2026 guidance for about 16% thyroid revenue growth and highlighted improvements in average revenue per test, DSO, turnaround time, account volume, and a debt-free balance sheet.
Interpace Biosciences (OTCQX: IDXG) reported Q4 2025 revenue of $9.2M and full-year 2025 revenue of $38.7M. Income from continuing operations was $22.8M in Q4 and $25.0M for 2025, driven by a one-time, non-cash deferred tax valuation allowance release. Thyroid revenue rose 14% in Q4 and 21% for FY, with thyroid test volume up 11% in Q4 and 13% for FY. The company paid off debt in Q4, increased cash availability by $4.3M year-over-year, and reported operational improvements including a 19% DSO reduction and 20% faster turnaround time.
Interpace Biosciences (OTCID: IDXG) reported preliminary unaudited 2025 revenue of approximately $38–39 million, with $34–35 million from thyroid testing, a ~21% increase versus 2024. The company initiated full-year 2026 revenue guidance of ~$40 million, implying ~16% thyroid revenue growth versus 2025. All Series C preferred shares converted into common stock, resulting in issuance of ~23,267,327 common shares and a pro forma share count of ~27.7 million. Management reports the company is debt-free after paying off 100% of outstanding debt in December and intends to seek a Nasdaq uplisting in 2026, although no assurance of success is given.
Interpace Biosciences (OTCID: IDXG) announced on December 3, 2025 that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to the facility's maturity date. The repayment satisfies obligations under the Loan and Security Agreement originally entered on October 29, 2021. By retiring the debt early, the company said it eliminates related interest expenses, increases operational flexibility, and strengthens its balance sheet to support future commercial growth. Management framed the move as part of a strategic turnaround to profitability and said the company continues to deliver record testing volumes and revenue for its thyroid tests.
Interpace Biosciences (OTCQX: IDXG) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $8.8 million; cash collections were $10.0 million. The company said thyroid test volume rose 12% year‑over‑year and thyroid revenue reached a record $8.8M, up 22% versus a prior pro forma quarter, while average revenue per test increased 5%. Management reported income from continuing operations of $1.0 million and adjusted EBITDA of $1.3 million. The company noted a 22% reduction in days sales outstanding and additional principal payments on long‑term debt tied to stronger cash flow.
Interpace Biosciences (OTCQX: IDXG) presented two significant scientific posters at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona. The first poster demonstrated that their testing platform successfully yielded molecular results in 86% (56 out of 65) of thyroid FNA cases previously deemed insufficient by another platform, using archival cytology slides.
The second poster analyzed 28,144 indeterminate thyroid nodules, showing that ThyGeNEXT identified BRAF V600E-like alterations in 4-6% and RAS-like alterations in ~19% of cases, while 76-77% were mutation-negative. The ThyraMIRv2 microRNA profiling further refined malignancy risk assessment, with over 90% of mutation-negative nodules classified as low risk.
Interpace Biosciences (OTCQX:IDXG) reported mixed Q2 2025 financial results, with net revenue of $9.2 million, down 23% year-over-year. Despite overall revenue decline, the company achieved record thyroid testing performance, with volume up 16% and revenue up 25% year-over-year to $8.7 million.
The company reported a Q2 loss from continuing operations of $0.5 million, compared to income of $2.5 million in Q2 2024, primarily impacted by $1.2 million in one-time charges related to PancraGEN testing discontinuation. Cash collections remained strong at $10.8 million, and preliminary July 2025 revenue showed a 54% year-over-year increase to $3.3 million.
Interpace is transitioning to focus exclusively on thyroid testing, following the loss of PancraGEN reimbursement. The company maintains a positive outlook for Q3 2025 and beyond as a thyroid-only diagnostics business.
Interpace Biosciences (OTCQX: IDXG) reported strong financial results for Q1 2025, with revenue reaching $11.5 million, a 13% increase year-over-year. The company achieved record thyroid test revenue of $8.0M (up 19%) and record thyroid test volume (up 16%). Cash collections hit record levels at $11.3 million, up 10% from the previous year.
Key financial metrics showed significant improvement, with gross profit margin increasing to 64% from 62%, and income from continuing operations reaching $1.8 million, a $0.9 million improvement over Q1 2024. The company initiated full-year 2025 revenue guidance of approximately $38 million, despite the anticipated loss of PancraGEN revenue after May 2, 2025.
Interpace Diagnostics (OTCQX: IDXG) announced the discontinuation of their PancraGEN® molecular diagnostic test for pancreatic cyst cancer risk assessment, effective May 2, 2025. This decision follows the Medicare Administrative Contractor Novitas Solutions' Local Coverage Determination ending reimbursement for the test.
The company will stop accepting specimens for PancraGEN testing after May 2, 2025, though they will continue processing tests without reimbursement between April 24 and May 2, 2025, to manage the transition. Despite PancraGEN's decade-long use in aiding pancreatic cancer diagnosis and reducing unnecessary surgeries, the loss of Medicare reimbursement makes the service unsustainable.
Interpace expects to maintain profitability through its thyroid testing franchise, ThyGeNEXT® + ThyraMIR®v2, and will implement a restructuring plan to adapt to these changes.
Interpace Biosciences (IDXG) reported preliminary Q4 and full-year 2024 results, highlighting record-breaking performance across key metrics. The company achieved a 21% year-over-year increase in Q4 Molecular Volume and a 17% increase for the full year, leading to double-digit revenue growth in both periods.
The company reached all-time highs in test volume, revenue, income, and cash collections for both Q4 and FY2024. Their ThyGeNEXT® + ThyraMIR®v2 testing services for indeterminate thyroid nodules showed particularly strong physician demand, significantly contributing to profitability.
While maintaining a positive outlook for 2025, management acknowledged uncertainty regarding PancraGEN® Medicare reimbursement, but indicated preparedness for potential non-coverage determination, emphasizing the strength and profitability of their Endo business unit as a solid foundation.